Breo fluticasone furoate/vilanterol regulatory update

FDA postponed the March 7 meeting of the agency's Pulmonary-Allergy Drugs Advisory Committee, which was set to discuss an NDA from Theravance and partner GlaxoSmithKline for Breo fluticasone furoate/vilanterol to treat chronic obstructive pulmonary disease (COPD). A GSK spokesperson said the meeting was postponed due to adverse weather and that the agency has not set a new date for the meeting. ...